Cargando…
Anti-TNF, a magic bullet in cancer immunotherapy?
Immune checkpoint blockers (ICB) have revolutionized cancer therapy. However, complete response is observed in a minority of patients and most patients develop immune-related adverse events (irAEs). These include colitis, which can be treated with anti-tumor necrosis factor (TNF) antibodies such as...
Autores principales: | Montfort, Anne, Dufau, Carine, Colacios, Céline, Andrieu-Abadie, Nathalie, Levade, Thierry, Filleron, Thomas, Delord, Jean-Pierre, Ayyoub, Maha, Meyer, Nicolas, Ségui, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857159/ https://www.ncbi.nlm.nih.gov/pubmed/31727152 http://dx.doi.org/10.1186/s40425-019-0802-y |
Ejemplares similares
-
The TNF Paradox in Cancer Progression and Immunotherapy
por: Montfort, Anne, et al.
Publicado: (2019) -
Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy
por: Montfort, Anne, et al.
Publicado: (2019) -
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Bertrand, Florie, et al.
Publicado: (2017) -
New Insights into the Role of Sphingolipid Metabolism in Melanoma
por: Carrié, Lorry, et al.
Publicado: (2020) -
Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma
por: Bilal, Fatima, et al.
Publicado: (2019)